Neurocrine Biosciences repurchases $179.4M of convertible notes, reduces debt by ~60% over two years

NEUROCRINE BIOSCIENCES INC

Repurchased $179.4M principal of 2.25% Convertible Senior Notes due 2024 for ~$224M cash plus stock-price-based component and accrued interest.
After repurchase, $201.8M principal remains outstanding; reduced from initial $517.5M.
CFO states debt reduction of ~60% over two years aims to minimize shareholder dilution.
Repurchases expected to close by June 14, 2022 under separate private agreements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.